News

Registrations are now open for participation in the EDCTP Forum 2027.

Global Health EDCTP3 is investing over €10 million in rapid tests, digital solutions and new approaches to overcome persistent barriers to tuberculosis control.

Global Health EDCTP3 invests €39 million to advance novel antimalarial compounds, a repurposed antiviral, and a triple therapy for severe malaria. Co-funding from Pharmaceutical companies, product development partnerships and research institutions brings the total investment to more than €76 million

In-Kind contributions to Additional Activities (IKAAs) are health research and capacity development projects that EDCTP Association member countries directly fund and manage with their own national funding and align with Global Health EDCTP3 goals.

Researchers and institutions from African Lusophone countries are making an increasingly important contribution to Global Health EDCTP3, already taking part in 25% of the project portfolio, a substantial increase compared to previous EDCTP Programme iterations.

From a child-friendly deworming pill to a simpler treatment for a deadly brain infection, EDCTP-funded trials have changed WHO recommendations. Now Global Health EDCTP3 is putting that experience into practice by joining the Global Clinical Trials Forum (GCTF).

This feature is the second in a series highlighting EDCTP-supported experts driving progress across global health. It showcases another ten influential figures whose work has been enabled through EDCTP fellowships, research projects and capacity-strengthening initiatives.

Madrid, Zaragoza and Barcelona will bring together international experts to discuss strategies for addressing health challenges in a globalised world.

Global Health EDCTP3 recorded a year of significant growth and impact in 2025, expanding its research portfolio, mobilising unprecedented partner investments and reinforcing its role as a leading global health partnership between Europe and Africa.